Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04537871 | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | active not recruiting | — | 350 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05150561 | Muscle Dysfunction in Patients With Haematological Diseases | active not recruiting | — | 216 | Rigshospitalet, DenmarkOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05428176 | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors | active not recruiting | N/A | 332 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06459024 | Master Framework For Relapse or Refractory Acute Myeloid Leukemia(IMPACT STREAM) | recruiting | — | 4,000 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 6 | Aug 14, 2026 | clinicaltrials |
| NCT06713837 | IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.(IMPACT-AML) | recruiting | Phase 3 | 339 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 7 | Aug 14, 2026 | clinicaltrials |
| NCT07232290 | Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | recruiting | Phase 2 | 60 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07384039 | Exercise Training in Patients With Myeloproliferative Neoplasms(MPN-Exercise) | recruiting | N/A | 80 | Hannover Medical SchoolOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | recruiting | Phase 1 / Phase 2 | 29 | Chaser Therapeutics, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01728402 | Pathogenesis of Hematologic Malignancies | enrolling by invitation | — | 5,000 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT02577926 | The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia(Ruxo-BEAT) | active not recruiting | Phase 2 | 207 | RWTH Aachen UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02732184 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | completed | Phase 1 | 21 | Immedica Pharma ABINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT03737955 | Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 | 36 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05115344 | Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | withdrawn | Phase 1 | 0 | Guizhou Bailing Group Pharmaceutical Co LtdINDUSTRY | 0 | Aug 13, 2026 | clinicaltrials |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | active not recruiting | Phase 3 | 160 | PharmaEssentiaINDUSTRY | 9 | Aug 13, 2026 | clinicaltrials |
| NCT07570407 | Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation(QiNKT-HSCT) | recruiting | — | 75 | University Hospital PilsenOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | recruiting | — | 30 | Haikou Affiliated Hospital of Central South University Xiangya School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT05188170 | Niclosamide in Pediatric Patients With Relapsed and Refractory AML | recruiting | Phase 1 | 16 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05444348 | Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)(ACT) | recruiting | N/A | 920 | Christoffer JohansenOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT07761702 | Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML | not yet recruiting | Phase 3 | 132 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | recruiting | Phase 2 / Phase 3 | 324 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04827719 | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS | completed | Phase 2 | 38 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05457010 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | active not recruiting | Phase 1 | 24 | Arcellx, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | not yet recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT00935090 | 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | active not recruiting | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 160 | Incyte CorporationINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT06285890 | Phase I Study of HC-7366 for Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06361641 | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes(PHEMOP) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial | suspended | Phase 1 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06529250 | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML(HADCEBPA2023) | recruiting | N/A | 148 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07131059 | MRD-positive AML Clinical Study | recruiting | N/A | 537 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07681258 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region(ASC4Young) | not yet recruiting | — | 80 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia(GAVE001) | not yet recruiting | Phase 2 | 20 | Florian KuchenbauerOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756034 | Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer(ONCO-OLIVIA) | recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02071901 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | completed | Phase 2 | 31 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03573024 | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | completed | Phase 2 | 36 | University of Colorado, DenverOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06265545 | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | recruiting | N/A | 458 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | recruiting | Phase 3 | 284 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07061145 | A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia(ED2024) | recruiting | — | 350 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07490288 | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | recruiting | N/A | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | not yet recruiting | — | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751991 | A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | recruiting | Phase 1 | 40 | Charm TherapeuticsINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2026source: clinicaltrials